{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T01:01:03Z","timestamp":1769043663321,"version":"3.49.0"},"reference-count":104,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T00:00:00Z","timestamp":1625529600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["British J Pharmacology"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:sec><jats:label\/><jats:p>Emerging data show that pregnant women with COVID\u201019 are at significantly higher risk of severe outcomes compared with non\u2010pregnant women of similar age. This review discusses the invaluable insight revealed from vaccine clinical trials in women who were vaccinated and inadvertently became pregnant during the trial period. It further explores a number of clinical avenues in their management and proposes a drug development strategy in line with clinical trials for vaccines and drug treatments for the drug development community. Little is known of the long\u2010term effects of COVID\u201019 on the mother and the baby. Our hypothesis that COVID\u201019 predisposes pregnant women to pre\u2010eclampsia or hypertensive disorders during pregnancy is supported by a clinical study, and this may also adversely impact a woman's cardiovascular disease risk later in life. It may also increase a woman's risk of pre\u2010eclampsia in subsequent pregnancy. This is an ever\u2010evolving landscape, and early knowledge for healthcare providers and drug innovators is offered to ensure benefits outweigh the risks. COVID\u201019 mRNA vaccines appear to generate robust humoral immunity in pregnant and lactating women. This novel approach to vaccination also offers new ways to therapeutically tackle disorders of many unmet medical needs.<\/jats:p><\/jats:sec><jats:sec><jats:title>LINKED ARTICLES<\/jats:title><jats:p>This article is part of a themed issue on The second wave: are we any closer to efficacious pharmacotherapy for COVID 19? (BJP 75th Anniversary). To view the other articles in this section visit <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bph.v179.10\/issuetoc\">http:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bph.v179.10\/issuetoc<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1111\/bph.15582","type":"journal-article","created":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T08:06:14Z","timestamp":1622793974000},"page":"2108-2120","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The impact of COVID\u201019 on pregnancy and therapeutic drug development"],"prefix":"10.1111","volume":"179","author":[{"given":"Allyah","family":"Abbas\u2010Hanif","sequence":"first","affiliation":[{"name":"Division of Drug Development MirZyme Therapeutics  Birmingham UK"},{"name":"Department of Cardiology Chelsea and Westminster Hospital NHS Foundation Trust  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Homira","family":"Rezai","sequence":"additional","affiliation":[{"name":"Division of Drug Development MirZyme Therapeutics  Birmingham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed Faraz","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Division of Drug Development MirZyme Therapeutics  Birmingham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8755-8546","authenticated-orcid":false,"given":"Asif","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Division of Drug Development MirZyme Therapeutics  Birmingham UK"},{"name":"School of Health Sciences University of Southampton  Southampton UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,7,6]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2015432"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000147365.86159.f5"},{"issue":"6","key":"e_1_2_11_4_1","first-page":"779","article-title":"Role of VEGF receptor\u20101 (Flt\u20101) in mediating calcium\u2010dependent nitric oxide release and limiting DNA synthesis in human trophoblast cells","volume":"76","author":"Ahmed A.","year":"1997","journal-title":"Laboratory Investigation"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12977"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/5584_2016_168"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14748"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14751"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14752"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2021.01.007"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3320"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-020-00420-2"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4109"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j3078"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39335.385301.BE"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0897.1998.tb00059.x"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvaa140"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.111.179358"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2017.02.015"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.15394"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2020.04.065"},{"key":"e_1_2_11_23_1","unstructured":"Centers for Disease Control and Prevention. (2021).SARS\u2010CoV\u20102 variant classifications and definitions. 26 March 2021. Available fromhttps:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/cases-updates\/variant-surveillance\/variant-info.html"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30360-3"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1016253"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2009.05.002"},{"key":"e_1_2_11_27_1","unstructured":"ClinicalTrials.gov. (2021a).Study to evaluate the safety tolerability and immunogenicity of SARS CoV\u20102 RNA vaccine candidate (BNT162b2) against COVID\u201019 in healthy pregnant women 18\u2009years of age and older. 26 March 2021. Available fromhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT04754594"},{"key":"e_1_2_11_28_1","unstructured":"ClinicalTrials.gov. (2021b).PK and safety of remdesivir for treatment of COVID\u201019 in pregnant and non\u2010pregnant women in the US. ClinicalTrials.gov Identifier: NCT04582266[cited 26 March 2021]. Available fromhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT04582266"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.660134"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118676"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajogmf.2020.100107"},{"key":"e_1_2_11_32_1","first-page":"1402","article-title":"Pre\u2010eclampsia, eclampsia, and hypertension","volume":"2008","author":"Duley L.","year":"2008","journal-title":"BMJ Clinical Evidence"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6925a1"},{"key":"e_1_2_11_34_1","unstructured":"European Medicines Agency. (2021).EMA starts first rolling review of a COVID\u201019 vaccine in the EU. 23 January 2021. Available fromhttps:\/\/www.ema.europa.eu\/en\/news\/ema-starts-first-rolling-review-covid-19-vaccine-eu"},{"key":"e_1_2_11_35_1","unstructured":"European Medicines Agency. (1996).Note for Guidance on Good Clinical Practice (CPMP\/ICH\/135\/95) ICH Topic E 6 Step 5 Consolidated Guideline 1.5.96 London. European Medicine Agency."},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18933-4"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0398-336"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2021.0038"},{"key":"e_1_2_11_39_1","volume-title":"Guidance for clinical trial sponsors: Establishment and operation of clinical trial data monitoring committees","author":"Food and Drug Administration","year":"2006"},{"key":"e_1_2_11_40_1","unstructured":"Food and Drug Administration. (2020a).Vaccines and Related Biological Products Advisory Committee: Pfizer\u2010BioNTech COVID\u201019 Vaccine (BNT162 PF\u201007302048) VRBPAC Briefing Document."},{"key":"e_1_2_11_41_1","unstructured":"Food and Drug Administration. (2020b).Vaccines and Related Biological Products Advisory Committee Meeting: Moderna COVID\u201019 Vaccine VRBPAC Briefing Document."},{"key":"e_1_2_11_42_1","doi-asserted-by":"crossref","unstructured":"Gilbert P.&Rudnick C.(2021).Newborn antibodies to SARS\u2010CoV\u20102 detected in cord blood after maternal vaccination. medRxiv p. 2021.02.03.21250579.","DOI":"10.1101\/2021.02.03.21250579"},{"key":"e_1_2_11_43_1","unstructured":"Gordon A. C. Mouncey P. R. Al\u2010Beidh F. Rowan K. M. Nichol A. D. Arabi Y. M. Annane D. Beane A. Bentum\u2010Puijk W. v. Berry L. R. Bhimani Z. Bonten M. J. M. Bradbury C. A. Brunkhorst F. M. Buzgau A. Cheng A. C. Detry M. A. Duffy E. J. Estcourt L. J. \u2026Derde L. P. G.(2021). \u201cInterleukin\u20106 Receptor Antagonists in Critically Ill Patients with Covid\u201019 \u2013 Preliminary report.\u201dMedRxiv."},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdr2.1696"},{"key":"e_1_2_11_45_1","doi-asserted-by":"crossref","unstructured":"Gray K. J. Bordt E. A Atyeo C. Deriso E. Akinwunmi B. Young N. Baez A. M. Shook L. L. Cvrk D. James K. De Guzman R. M. Brigida S. Diouf K. Goldfarb I. Bebell L. M. Yonker L. M. Fasano Rabi S. A. Elovitz M. A. Alter G. Edlow A. G.(2021).COVID\u201019 vaccine response in pregnant and lactating women: A cohort study. medRxiv.","DOI":"10.1101\/2021.03.07.21253094"},{"key":"e_1_2_11_46_1","doi-asserted-by":"crossref","unstructured":"Gray K. J. Bordt E. A. Atyeo C. Deriso E. Akinwunmi B. Young N. Baez A. M. Shook L. L. Cvrk D. James K. De Guzman R. M. Brigida S. Diouf K. Goldfarb I. Bebell L. M. Yonker L. M. Fasano A. Rabi S. A. Elovitz M. A. \u2026Edlow A. G.(2021). \"COVID\u201019 vaccine response in pregnant and lactating women: A cohort study.\" medRxiv: 2021.2003.2007.21253094.","DOI":"10.1101\/2021.03.07.21253094"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1164\/arrd.1981.124.5.593"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1570031"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9378(94)05009-x"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.1017"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvaa106"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-09762-y"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021436"},{"key":"e_1_2_11_54_1","unstructured":"Horby P. W. Pessoa\u2010Amorim G. Peto L. Brightling C. E. Sarkar R. Thomas K. Jeebun V. Ashish A. Tully R. Chadwick D. Sharafat M. Stewart R. Rudran B. Baillie J. K. Buch M. H. Chappell L. C. Day J. N. Furst S. N. Jaki T. \u2026Landray M. J.(2021a).Tocilizumab in patients admitted to hospital with COVID\u201019 (RECOVERY): Preliminary results of a randomised controlled open\u2010label platform trial. medRxiv: p. 2021.02.11.21249258."},{"key":"e_1_2_11_55_1","unstructured":"Horby P. W. Pessoa\u2010Amorim G. Peto L. Brightling C. E. Sarkar R. Thomas K. Jeebun V. Ashish A. Tully R. Chadwick D. Sharafat M. Stewart R. Rudran B. Baillie J. K. Buch M. H. Chappell L. C. Day J. N. Furst S. N. Jaki T. \u2026Landray M. J.(2021b).Convalescent plasma in patients admitted to hospital with COVID\u201019 (RECOVERY): A randomised controlled open\u2010label platform trial. medRxiv p. 2021.03.09.21252736."},{"key":"e_1_2_11_56_1","volume-title":"Intensive Care National Audit & Research Centre report on COVID\u201019 536 in critical care: England, Wales and Northern Ireland","author":"Intensive Care National Audit & Research Centre","year":"2021"},{"key":"e_1_2_11_57_1","unstructured":"International Conference on Harmonisation. (2009).ICH guideline M3(R2) guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. 10 January 2021. Available fromhttps:\/\/database.ich.org\/sites\/default\/files\/M3_R2__Guideline.pdf"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.9241"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00454-7"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30216-2"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031893"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajogmf.2020.100113"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031884"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yjmcc.2020.08.008"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0230295"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2020.12.1221"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.109.130765"},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.1286"},{"key":"e_1_2_11_69_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n597"},{"key":"e_1_2_11_70_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI17189"},{"key":"e_1_2_11_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajogmf.2020.100164"},{"key":"e_1_2_11_72_1","volume-title":"Public assessment report authorisation for temporary supply: COVID\u201019 Vaccine AstraZeneca, solution for injection in multidose container COVID\u201019 Vaccine (ChAdOx1\u2010S [recombinant])","author":"Medicines & Healthcare products Regulatory Agency","year":"2020"},{"key":"e_1_2_11_73_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000004339"},{"key":"e_1_2_11_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2020.06.026"},{"key":"e_1_2_11_75_1","first-page":"196","article-title":"Safety and efficacy of inhaled nebulised interferon beta\u20101a (SNG001) for treatment of SARS\u2010CoV\u20102 infection: A randomised, double\u2010blind, placebo\u2010controlled, phase 2 trial","author":"Monk P. D.","year":"2020","journal-title":"The Lancet Respiratory Medicine"},{"key":"e_1_2_11_76_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910993"},{"key":"e_1_2_11_77_1","doi-asserted-by":"publisher","DOI":"10.1002\/uog.23619"},{"key":"e_1_2_11_78_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000004050"},{"key":"e_1_2_11_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2020.12.008"},{"key":"e_1_2_11_80_1","doi-asserted-by":"crossref","unstructured":"Patone M. Thomas K. Hatch R. Tan P. S. Coupland C. Liao W. Mouncey P. Harrison D. Rowan K. Horby P. Watkinson P. &Hippisley\u2010Cox J.(2021).Analysis of severe outcomes associated with the SARS\u2010CoV\u20102 Variant of Concern 202012\/01 in England using ICNARC Case Mix Programme and QResearch databases. medRxiv p. 2021.03.11.21253364.","DOI":"10.1101\/2021.03.11.21253364"},{"key":"e_1_2_11_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.placenta.2011.09.020"},{"key":"e_1_2_11_82_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.3557"},{"key":"e_1_2_11_83_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.118.313276"},{"key":"e_1_2_11_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2012.06.068"},{"key":"e_1_2_11_85_1","unstructured":"RECOVERY Trial. (2020).Randomised evaluation of COVID\u201019 therapy (RECOVERY). 23 January 2021. Available fromhttps:\/\/www.recoverytrial.net\/files\/recovery-protocol-v12-1-2020-12-16.pdf"},{"key":"e_1_2_11_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(99)70239-5"},{"key":"e_1_2_11_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2020.101768"},{"key":"e_1_2_11_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.02.017"},{"key":"e_1_2_11_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2021.03.001"},{"key":"e_1_2_11_90_1","unstructured":"Royal College of Obstetricians and Gynaecologists. (2020a).Updated advice on COVID\u201019 vaccination in pregnancy and women who are breastfeeding. 23 January 2021."},{"key":"e_1_2_11_91_1","unstructured":"Royal College of Obstetricians and Gynaecologists. (2020b).Coronavirus (COVID\u201019) infection in pregnancy. RCOG guideline. 23 January 2021. Available fromhttps:\/\/www.rcog.org.uk\/globalassets\/documents\/guidelines\/2020-10-14-coronavirus-covid-19-infection-in-pregnancy-v12.pdf"},{"key":"e_1_2_11_92_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034201"},{"key":"e_1_2_11_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2020.101814"},{"key":"e_1_2_11_94_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2020.00317"},{"key":"e_1_2_11_95_1","doi-asserted-by":"publisher","DOI":"10.3390\/antiox9070598"},{"key":"e_1_2_11_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2020.06.022"},{"key":"e_1_2_11_97_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-2360"},{"key":"e_1_2_11_98_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0238215"},{"key":"e_1_2_11_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(20)30484-8"},{"key":"e_1_2_11_100_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0343-0"},{"key":"e_1_2_11_101_1","doi-asserted-by":"crossref","unstructured":"Vousden N. Bunch K. Morris E. Simpson N. Gale C. O'Brien P. Quigley M. Brocklehurst P. Kurinczuk J. J. &Knight M.(2021).The incidence characteristics and outcomes of pregnant women hospitalized with symptomatic and asymptomatic SARS\u2010CoV\u20102 infection in the UK from March to September 2020: A national cohort study using the UK Obstetric Surveillance System (UKOSS). MedRxiv.","DOI":"10.1371\/journal.pone.0251123"},{"key":"e_1_2_11_102_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.001631"},{"key":"e_1_2_11_103_1","unstructured":"World Health Organization. (2021).Draft landscape and tracker of COVID\u201019 candidate vaccines[cited 10 January 2021]. Available fromhttps:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines"},{"key":"e_1_2_11_104_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6944e3"},{"key":"e_1_2_11_105_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2020.0878"}],"container-title":["British Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bph.15582","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bph.15582","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bph.15582","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T00:09:01Z","timestamp":1692835741000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bph.15582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,6]]},"references-count":104,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1111\/bph.15582"],"URL":"https:\/\/doi.org\/10.1111\/bph.15582","archive":["Portico"],"relation":{},"ISSN":["0007-1188","1476-5381"],"issn-type":[{"value":"0007-1188","type":"print"},{"value":"1476-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,6]]},"assertion":[{"value":"2021-02-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}